Top

Published in:

Open Access 01-06-2013

Association Between IL-6 Concentration and Diabetes-Related Variables in DM1 Patients with and without Microvascular Complications

Authors: Malgorzata Wegner, Aleksandra Araszkiewicz, Maria Piorunska-Stolzmann, Bogna Wierusz-Wysocka, Dorota Zozulinska-Ziolkiewicz

Published in: Inflammation | Issue 3/2013

Abstract

Interleukin 6 (IL-6) plays an important role in the initiation and acceleration of chronic inflammation and could contribute to development of microvascular complications in patients with type 1 diabetes (DM1). Therefore, this study was aimed to investigate the association between concentration of IL-6 in relation to glucose control, lipid profile, and body mass index (BMI) in 69 DM1 patients subdivided according to the absence or presence of microvascular complications. BMI, level of fasting plasma glucose (FPG), and concentrations of total cholesterol (TCH), LDL cholesterol (LDL-C), and IL-6 were higher in DM1 patients compared to the control group. In DM1 patients, IL-6 concentration was positively correlated with level of FPG, LDL-C, TCH concentrations, and BMI. These correlations were stronger in the subgroup of patients with microvascular complications. In addition, BMI independently influences IL-6 concentration in DM1 patients. In conclusion, elevated IL-6 concentration is associated with diabetes-related variables which could accelerate progression of microvascular complications in DM1 patients.

Abi Khalil, C., R. Roussel, K. Mohammedi, et al. 2012. Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol 19: 374–381.PubMedCrossRef

Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.PubMedCrossRef

Wegner, M., A. Araszkiewicz, A. Pioruńska-Mikołajczak, et al. 2009. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clinical Biochemistry 42: 1621–1627.PubMedCrossRef

Marcovecchio, M.L., R.N. Dalton, A.T. Prevost, et al. 2009. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 32: 658–663.PubMedCrossRef

Aguiar, L.G., N.R. Villela, and E. Bonskela. 2007. Microcirculation in diabetes implications for chronic complications and treatment of the disease. Arg Bras Endorcrinol Metabol 51: 204–211.

Devaraj, S., A.T. Cheung, I. Jialal, et al. 2007. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56: 2790–2796.PubMedCrossRef

Astrup, A.S., L. Tarnow, L. Pietraszek, et al. 2008. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years. Diabetes Care 31: 1170–1176.PubMedCrossRef

Croker, B.A., H. Kiu, M. Pellegrini, et al. 2012. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunology and Cell Biology 90: 124–129.PubMedCrossRef

Waetzig, G.H., and S. Rose-John. 2012. Hitting a complex target: an update on interleukin-6trans-signalling. Expert Opinion on Therapeutic Targets 16: 225–236.PubMedCrossRef

10.

Mihara, M., M. Hashizume, H. Yoshida, et al. 2012. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical Science 122: 143–159.PubMedCrossRef

11.

Gabay, C. 2006. Interleukin-6 and chronic inflammation. Arthritis Research & Therapy 8(Suppl 2): 3.CrossRef

12.

Kulseng, B., L. Vatten, and T. Espevik. 1999. Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease. Acta Diabetologica 36: 99–105.PubMedCrossRef

13.

Targher, G., L. Zenari, L. Bertolini, et al. 2001. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 24: 956–957. Letter.PubMedCrossRef

14.

Saraheimo, M., A.M. Teppo, C. Forsblom, et al. 2003. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46: 1402–1407.PubMedCrossRef

15.

Jialal I, Kaur H. 2013. The role of toll-like receptors in diabetes-induced inflammation: implications for vascular complications. Current Diabetes Reports (In press)

16.

Araszkiewicz, A., D. Zozulinska-Ziolkiewicz, M. Trepinska, et al. 2008. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Research and Clinical Practice 81: 61–67.PubMedCrossRef

17.

American Diabetes Association. 2007. Standards of medical care in diabetes—2007. Diabetes Care 30: 4–41.CrossRef

18.

Wilkinson, C.P., F.L. Ferris, R.E. Klein, et al. 2003. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110: 1677–1682.PubMedCrossRef

19.

KDOQI. 2007. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. American Journal of Kidney Diseases 49: 12–154.CrossRef

20.

Jeppsson, J.O., U. Kobold, J. Barr, et al. 2002. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical Chemistry and Laboratory Medicine 40: 78–79.PubMedCrossRef

21.

Hartge, M.M., T. Unger, and U. Kintscher. 2007. The endothelium and vascular inflammation in diabetes. Diabetes & Vascular Disease Research 4: 84–88.CrossRef

22.

Fisman, E.Z., and A. Tenenbaum. 2010. The ubiquitous interleukin-6: a time for reappraisal. Cardiovascular Diabetology 11: 9–62.

23.

Navarro, J.F., and M. Carmen. 2005. Role of inflammation in diabetic complications. Nephrology, Dialysis, Transplantation 20: 2601–2604.PubMedCrossRef

24.

Munch, I.C., M. Larsen, L. Kessel, et al. 2011. Cumulative glycemia and microangiopathy in subjects with impaired glucose regulation in the Inter 99 study. Diabetes Research and Clinical Practice 91: 226–232.PubMedCrossRef

25.

Nevado, J., C. Peiró, S. Vallejo, et al. 2005. Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. British Journal of Pharmacology 146: 268–279.PubMedCrossRef

26.

Illán-Gómez, F., M. Gonzálvez-Ortega, I. Orea-Soler, et al. 2012. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obesity Surgery 22: 950–955.PubMedCrossRef

27.

Sommer, G., S. Kralisch, V. Stangl, et al. 2009. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. Journal of Cellular Biochemistry 106: 729–737.PubMedCrossRef

28.

Mohamed-Ali, V., S. Goodrick, and A. Rawesh. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. Journal of Clinical Endocrinology and Metabolism 82: 4196–4200.PubMedCrossRef

29.

Greenberg, A.S., R.P. Nordan, J. McIntosh, et al. 1992. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3–L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Research 52: 4113–4116.PubMed

30.

Campfield, L.A., F.J. Smith, Y. Guisez, et al. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546–549.PubMedCrossRef

31.

Fawaz, L., A.E. Elwan, Y.H. Kamel, et al. 2009. Value of C-reactive protein and IL-6 measurements in type 1 diabetes mellitus. Arch Med Sci 3: 383–390.

32.

Nakamura, N., G. Hasegawa, H. Obayashi, et al. 2003. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Research and Clinical Practice 61: 93–101.PubMedCrossRef

33.

Nalysnyk, L., M. Hernandez-Medina, and G. Krishnarajah. 2010. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes, Obesity & Metabolism 12: 288–298.CrossRef

34.

Lau, D.C., B. Dhillon, H. Yan, et al. 2005. Adipokines: molecular links between obesity and atherosclerosis. American Journal of Physiology-Heart and Circulatory Physiology 288: 2031–2041.CrossRef

35.

Georgescu, A., N. Alexandru, E. Andrei, et al. 2012. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. Journal of Thrombosis and Haemostasis 10: 680–691.PubMedCrossRef

36.

Kolluru, G.K., S.C. Bir, and C.G. Kevil. 2012. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012: 918267.PubMed

37.

Jisieike-Onuigbo, N.N., E.I. Unuigbe, O.A. Kalu, et al. 2011. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Nigerian Journal of Clinical Practice 14: 171–175.PubMedCrossRef

38.

Dalla Vestra, M., M. Mussap, P. Gallina, et al. 2005. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Journal of the American Society of Nephrology 16: 78–82.CrossRef

39.

Marketou, M.E., E.A. Zacharis, S. Koukouraki, et al. 2008. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. Journal of Human Hypertension 22: 191–196.PubMedCrossRef

Title: Association Between IL-6 Concentration and Diabetes-Related Variables in DM1 Patients with and without Microvascular Complications
Authors: Malgorzata Wegner
Aleksandra Araszkiewicz
Maria Piorunska-Stolzmann
Bogna Wierusz-Wysocka
Dorota Zozulinska-Ziolkiewicz
Publication date: 01-06-2013
Publisher: Springer US
Published in: Inflammation / Issue 3/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-013-9598-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association Between IL-6 Concentration and Diabetes-Related Variables in DM1 Patients with and without Microvascular Complications

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Anti-inflammatory Effect of Protocatechuic Aldehyde on Myocardial Ischemia/Reperfusion Injury In Vivo and In Vitro

Activation of RhoA in Alcohol-Induced Intestinal Barrier Dysfunction

Periodontal Disease in Patients with Psoriatic Arthritis

Antiapoptotic and Proapoptotic Signaling of Cyclophilin A in Endothelial Cells

Flos Lonicerae Extracts and Chlorogenic Acid Protect Human Umbilical Vein Endothelial Cells from the Toxic Damage of Perfluorooctane Sulphonate

Oligopeptidases B from Trypanossoma cruzi and Trypanossoma brucei Inhibit Inflammatory Pain in Mice by Targeting Serotoninergic Receptors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page